Antigen-specific therapy against Type 1 diabetes: Mechanisms and perspectives

Xiaoxiao Wan, Habib Zaghouani

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Type 1 diabetes (T1D) is an immune-mediated disease that occurs when the insulin-producing â'cells of the pancreatic islets are destroyed by an inflammatory process perpetuated by cells of the immune system. The logical approach to suppress T1D is to inactivate or eliminate the lymphocytes responsible for inducing inflammation and targeting the â'cells. Antigen-specific approaches have been devised and were able to target inflammatory lymphocytes and induce apoptosis or block trafficking to pancreatic islets. Lack of costimulation, expansion of Tregs and bystander suppression are likely mechanisms by which antigen-specific treatments modulate pathogenic T cells. This strategy, however, while prevents the onset of T1D, could not overcome overt T1D, perhaps because of collateral damage to the islet vascular network. Recent developments indicate that donor endothelial stem cell precursors can repair the islets vascular niche and assist antigen-specific therapy against overt T1D.

Original languageEnglish
Pages (from-to)155-164
Number of pages10
Issue number2
StatePublished - Feb 2014


  • -cell formation
  • Type 1 diabetes
  • antigen-specific therapy
  • immune modulation
  • islet endothelial network repair


Dive into the research topics of 'Antigen-specific therapy against Type 1 diabetes: Mechanisms and perspectives'. Together they form a unique fingerprint.

Cite this